Testing YB-101 for safety and effectiveness in Graves' disease
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests an investigational drug called YB-101 for people with Graves' disease, whether or not they have thyroid eye disease. The goal is to see if the drug is safe and can help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Graves' disease, confirmed by a blood test for thyroid-stimulating hormone receptor antibodies (TRAbs).
- You either have thyroid eye disease (TED) or have no signs of it during an eye exam.
- You have not been treated with radioactive iodine or had your thyroid gland removed.
- You have not taken thyroid hormone medications (like levothyroxine) in the last 6 weeks.
- You are not currently using or have not recently used the drug teprotumumab.
- Your hyperthyroidism is caused by Graves' disease, not by other conditions like a toxic nodule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, BHV-1300, to see if it can safely and effectively reduce the overactive thyroid caused by Graves' disease, an autoimmune condition. It may offer a new option for people who haven't had certain prior treatments.
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
This trial tests a new drug called IMVT-1402 for adults with Graves' disease whose thyroid is still overactive despite taking antithyroid medication. The goal is to see if the drug can safely help control thyroid hormone levels.
This trial tests a new medicine called REGN24493 that may help control Graves' disease by blocking a specific receptor in the body. It is designed for adults who have been diagnosed with Graves' disease and are currently stable on their thyroid levels.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
This study looks at people newly diagnosed with Graves' disease to see who might develop thyroid eye disease, a condition that can affect the eyes. It aims to find early signs so that treatment can be started sooner.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.